4-Pentylcyclohexa-2,5-dien-1-one | 189358-10-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-Pentylcyclohexa-2,5-dien-1-one
• CAS: 189358-10-9
• 化学式: C₁₁H₁₆O
• 分子量: 164.24
• InChiKey: PPCRSEVCDBIKRH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• 4-Aryl quinols and analogs thereof as therapeutic agents
  申请人：——

  公开号：US20040220236A1

  公开（公告）日：2004-11-04

  The present invention pertains to compounds of the formula (I) which are, inter alia, antiprolilferative agents, anticancer agents, anitimycohacterial agents, antituberculosis agents, and/or thioredoxin/thioredoxin reductase inhibitor: wherein: Q is ═O or ═N—S(═O) 2 —R Q ; R Q is -II or optionally substituted C 1-7 alkyl, C 3-20 heterocyclyl, or C 5-20 aryl; Ar is optionally substituted C 5-20 aryl; R O is an oxy substituent; the bond marked &agr; is a single bond or a double bond; the bond marked &bgr; is a single bond or a double bond; R 3 and R 5 are each independently ring substituents; R 2 and R 6 are each independently ring substituents; and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, for example, in the treatment of proliferative conditions, (e.g., cancer), mycobacterial infections (e.g., tuberculosis), and/or conditions mediated by thioredoxin/thioredoxin reductase. 1

  本发明涉及化合物的公式（I），其是抗增殖剂，抗癌剂，抗结核菌剂，抗结核病剂和/或硫氧还蛋白/硫氧还蛋白还原酶抑制剂，其中：Q是═O或═N-S（═O）2-RQ; RQ是-II或可选取代的C1-7烷基，C3-20杂环基或C5-20芳基; Ar是可选取代的C5-20芳基; RO是氧代取代基; 标记为&agr;的键是单键或双键; 标记为&bgr;的键是单键或双键; R3和R5各自独立地是环取代基; R2和R6各自独立地是环取代基; 以及其药学上可接受的盐，酯，酰胺，溶剂化合物，水合物和保护形式。本发明还涉及包含这种化合物的制药组合物，以及这种化合物和组合物的使用，无论是体外还是体内，例如，用于治疗增殖性疾病（例如癌症），结核菌感染（例如结核病）和/或由硫氧还蛋白/硫氧还蛋白还原酶介导的疾病。
• 4-aryl quinols and analogs thereof as therapeutic agents
  申请人：Stevens Francis Graham Malcolm

  公开号：US20060287396A1

  公开（公告）日：2006-12-21

  The present invention pertains to compounds of the following formula, which are, inter alia, antiproliferative agents, anticancer agents, antimycobacterial agents, antituberculosis agents, and/or thioredoxin/thioredoxin reductase inhibitors: wherein: Q is ═O or ═N—S(═O) 2 —R Q ; R Q is —H or optionally substituted C 1-7 alkyl, C 3-20 heterocyclyl, or C 5-20 aryl; Ar is optionally substituted C 5-20 aryl; R O is an oxy substituent; the bond marked α is a single bond or a double bond; the bond marked β is a single bond or a double bond; R 3 and R 5 are each independently ring substituents; R 2 and R 6 are each independently ring substituents; and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, for example, in the treatment of proliferative conditions, (e.g., cancer), mycobacterial infections (e.g., tuberculosis), and/or conditions mediated by thioredoxin/thioredoxin reductase.

  本发明涉及以下式的化合物，它们是抗增殖剂、抗癌剂、抗分枝杆菌剂、抗结核菌剂和/或硫氧还蛋白/硫氧还蛋白还原酶抑制剂，其中：Q为═O或═N—S(═O)2—RQ；RQ为—H或可选取代的C1-7烷基、C3-20杂环基或C5-20芳基；Ar为可选取代的C5-20芳基；RO为氧代取代基；标记为α的键为单键或双键；标记为β的键为单键或双键；R3和R5各自独立地为环取代基；R2和R6各自独立地为环取代基；以及其药学上可接受的盐、酯、酰胺、溶剂化合物、水合物和保护形式。本发明还涉及包括这样的化合物的制药组合物，以及这样的化合物和组合物的使用，无论是体外还是体内，例如在治疗增殖性疾病（例如癌症）、分枝杆菌感染（例如结核病）和/或由硫氧还蛋白/硫氧还蛋白还原酶介导的疾病中。
• 4-ARYL QUINOLS AND ANALOGS THEREOF AS THERAPEUTIC AGENTS
  申请人：Cancer Research Technology Limited

  公开号：EP1404659A1

  公开（公告）日：2004-04-07
• US7144893B2
  申请人：——

  公开号：US7144893B2

  公开（公告）日：2006-12-05
• [EN] 4-ARYL QUINOLS AND ANALOGS THEREOF AS THERAPEUTIC AGENTS<br/>[FR] 4-ARYL QUINOLS ET LEURS ANALOGUES UTILISES EN TANT QU'AGENTS THERAPEUTIQUES
  申请人：CANCER REC TECH LTD

  公开号：WO2003004479A1

  公开（公告）日：2003-01-16

  The present invention pertains to compounds of the formula (1), which are, inter alia, antiproliferative agents, anticancer agents, antimycobacterial agents, antituberculosis agents, and/or thioredoxin/thioredoxin reductase inhibitors: wherein: Q is =O or =N-S(=O)2-RQ;RQ is -H or optionally substituted C¿1-7?alkyl, C3-20heterocyclyl, or C5-20aryl; Ar is optionally substituted C5-20aryl; R?o¿ is an oxy substituent; the bond marked α is a single bond or a double bond; the bond marked ß is a single bond or a double bond; R?3 and R5¿ are each independently ring substituents; R?2 and R6¿ are each independently ring substituents; and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, for example, in the treatment of proliferative conditions, (e.g., cancer), mycobacterial infections (e.g., tuberculosis), and/or conditions mediated by thioredoxin/thioredoxin reductase.